Cover Image

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis

Saved in:

Bibliographic Details
Main Authors:	Emily Seale, MPH (Author), Genevieve Gavigan, MASc, MD (Author)
Format:	Book
Published:	Elsevier, 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
by: Makoto Ito, et al.
Published: (2023)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
by: S. Martínez-Fernández, et al.
Published: (2023)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
by: Nicolas Caudrelier, MD, et al.
Published: (2023)

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab
by: Yan Yang, et al.
Published: (2023)

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients
by: Francesco Piscazzi, et al.
Published: (2023)

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report
by: Ting Pan, et al.
Published: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib
by: Takeshi Koga, et al.
Published: (2024)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
by: Jannett Nguyen, MD, et al.
Published: (2021)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
by: L. Mastorino, et al.
Published: (2023)

Effectiveness of upadacitinib in Japanese patients with prurigo‐type atopic dermatitis: Four cases report
by: Keiji Kosaka, et al.
Published: (2023)

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
by: Andrew Blauvelt, et al.
Published: (2024)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
by: Hagino T, et al.
Published: (2023)

The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2023)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020)

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
by: Shawn G. Kwatra, et al.
Published: (2024)

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study
by: Nobukazu Hayashi, et al.
Published: (2023)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
by: Teppei Hagino, et al.
Published: (2024)

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
by: Ana Batalla, et al.
Published: (2023)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
by: Norito Katoh, et al.
Published: (2023)

Successful Treatment with Upadacitinib of Patient with Persistent Head and Neck Atopic Dermatitis Refractory to Dupilumab: A Case Report
by: So Yun Park, et al.
Published: (2024)

Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata,
by: Guilherme Muzy
Published: (2024)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024)

Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series
by: Neda Shahriari, MD, et al.
Published: (2024)

Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis
by: Takayuki Tanji, et al.
Published: (2023)

Real-World Experience of Upadacitinib Dosing Reduction in Patients With Moderate Atopic Dermatitis: A Case Series Study in Taiwan
by: Yang-Yi Chen, et al.
Published: (2024)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
by: Celeste M. Boesjes, et al.
Published: (2023)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024)

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
by: April W. Armstrong, et al.
Published: (2024)

Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis
by: Peter Yi Ch'en, BS, et al.
Published: (2024)

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
by: Luigi Gargiulo, et al.
Published: (2024)

Staphylococcus aureus colonization on antecubital non-exacerbated atopic dermatitis patient compared to healthy children
by: Nur Khamidah, et al.
Published: (2019)

Upadacitinib for prurigo nodularis
by: Clara Muntaner-Virgili, MD, et al.
Published: (2024)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023)

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
by: Eric L. Simpson, et al.
Published: (2024)